These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 23010883

  • 1. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
    Simon JA, Recknor C, Moffett AH, Adachi JD, Franek E, Lewiecki EM, McClung MR, Mautalen CA, Ragi-Eis S, Nicholson GC, Muschitz C, Nuti R, Törring O, Wang A, Libanati C.
    Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
    [Abstract] [Full Text] [Related]

  • 2. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
    Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, Kivitz AJ, Fuerst T, Wang H, Austin M, Libanati C.
    Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
    [Abstract] [Full Text] [Related]

  • 3. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
    Bilezikian JP, Lin CJF, Brown JP, Wang AT, Yin X, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C, Chines A.
    Osteoporos Int; 2019 Sep; 30(9):1855-1864. PubMed ID: 31201481
    [Abstract] [Full Text] [Related]

  • 4. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.
    McClung MR, Zanchetta JR, Høiseth A, Kendler DL, Yuen CK, Brown JP, Stonkus S, Goemaere S, Recknor C, Woodson GC, Bolognese MA, Franek E, Brandi ML, Wang A, Libanati C.
    J Clin Densitom; 2013 Sep; 16(2):250-6. PubMed ID: 22572531
    [Abstract] [Full Text] [Related]

  • 5. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J.
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [Abstract] [Full Text] [Related]

  • 6. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
    Watts NB, Hattersley G, Fitzpatrick LA, Wang Y, Williams GC, Miller PD, Cosman F.
    Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
    [Abstract] [Full Text] [Related]

  • 7. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC.
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [Abstract] [Full Text] [Related]

  • 8. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C.
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [Abstract] [Full Text] [Related]

  • 9. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.
    Bolognese MA, Teglbjærg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, Høiseth A, Lakatos P, Moffett AH, Lorenc RS, Wang A, Libanati C.
    J Clin Densitom; 2013 Oct; 16(2):147-53. PubMed ID: 22521543
    [Abstract] [Full Text] [Related]

  • 10. Denosumab: an antifracture therapy for postmenopausal women with osteoporosis.
    Jiang X, Schnatz PF.
    Menopause; 2013 Feb; 20(2):117-9. PubMed ID: 23299707
    [No Abstract] [Full Text] [Related]

  • 11. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S.
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [Abstract] [Full Text] [Related]

  • 12. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
    Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O, Gallagher JC, Farrerons J, Wang A, Franchimont N, San Martin J, Grauer A, McClung M.
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
    [Abstract] [Full Text] [Related]

  • 13. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
    Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA.
    J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
    [Abstract] [Full Text] [Related]

  • 14. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.
    Genant HK, Libanati C, Engelke K, Zanchetta JR, Høiseth A, Yuen CK, Stonkus S, Bolognese MA, Franek E, Fuerst T, Radcliffe HS, McClung MR.
    Bone; 2013 Oct; 56(2):482-8. PubMed ID: 23871852
    [Abstract] [Full Text] [Related]

  • 15. The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis.
    Beck TJ, Fuerst T, Gaither KW, Sutradhar S, Levine AB, Hines T, Yu CR, Williams R, Mirkin S, Chines AA.
    Bone; 2015 Aug; 77():115-9. PubMed ID: 25917574
    [Abstract] [Full Text] [Related]

  • 16. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [Abstract] [Full Text] [Related]

  • 17. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM, Iranikhah MM, Wilborn TW.
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [Abstract] [Full Text] [Related]

  • 18. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, AMG 162 Bone Loss Study Group.
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [Abstract] [Full Text] [Related]

  • 19. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
    Nakamura T, Matsumoto T, Sugimoto T, Shiraki M.
    Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
    [Abstract] [Full Text] [Related]

  • 20. Update on denosumab in postmenopausal osteoporosis--recent clinical data.
    Muschitz C, Fahrleitner-Pammer A, Huber J, Preisinger E, Kudlacek S, Resch H.
    Wien Med Wochenschr; 2012 Sep; 162(17-18):374-9. PubMed ID: 22688622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.